Skip to content
OpenCapital
Get started

MapLight Therapeutics, Inc. MPLT Exchange Offer (Note 12)

Exchange Offer (Note 12) at other companies

LBR
LB Pharmaceuticals Inc Common StockLBRX
$28.57M—

Other financials

Income statement

See full
Operating income-$64.5M-174%
Net income-$60.7M-172%
EPS (diluted)-$1.34+95.4%

Balance sheet

See full
Cash & equivalents$55.7M—
Total debt$5.6M—
Total equity$399.8M+285%
Total assets$418.8M—

Cash flow

See full
Operating cash flow-$51.2M-100%
CapEx$24.0K—
Free cash flow-$51.2M—

Valuation

See full
Market cap$1.39B+100%
Enterprise value$1.34B—

Returns & leverage

See full
Return on equity-216.8%—
Debt / equity0×—
Current ratio22.9×—

Where this comes from

Reported directly by MapLight Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ConversionOfStockAmountConverted1.

The official record: MapLight Therapeutics, Inc. ’s 10-K, filed March 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's exchange offer (note 12).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's exchange offer (note 12)?
MapLight Therapeutics, Inc. (MPLT) reported exchange offer (note 12) of $126.92M in Q4 2025.
What does exchange offer (note 12) mean?
This represents the non-cash exchange of one class of equity or debt security into another, typically common stock, as part of a recapitalization or debt restructuring. It reflects changes in the capital structure that do not involve immediate cash flows but significantly alter the ownership profile. Investors monitor this to understand the impact of conversion events on share count and capital structure stability.